Drug Trial Radar · NCT01170663
A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma
Last checked: Nov 20, 2026Latest source record: Sep 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
665
Actual
Start
Dec 2010
Primary completion
Jul 2013
Study completion Feb 2017
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jul 27, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III randomized multicenter double-blind, placebo controlled trial evaluating the safety and efficacy of paclitaxel plus ramucirumab (IMC-1211B) drug product (DP) compared to paclitaxel plus placebo.
Conditions
- Gastric Cancer
Interventions
Ramucirumab (IMC-1211B) DPBiological
8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle
PlaceboDrug
Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle
PaclitaxelDrug
Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival Time (OS)Time frame: Randomization up to 27.5 months
Locations
167 sites in 26 countries. Site status is shown where the registry gives one.
ImClone Investigational Site
Burbank, California
ImClone Investigational Site
Los Angeles, California
ImClone Investigational Site
San Francisco, California
ImClone Investigational Site
Jacksonville, Florida
ImClone Investigational Site
Miramar, Florida
ImClone Investigational Site
Atlanta, Georgia
ImClone Investigational Site
Honolulu, Hawaii
ImClone Investigational Site
East Orange, New Jersey
ImClone Investigational Site
Albuquerque, New Mexico
ImClone Investigational Site
New York, New York
ImClone Investigational Site
Chattanooga, Tennessee
ImClone Investigational Site
Houston, Texas
ImClone Investigational Site
Seattle, Washington
ImClone Investigational Site
Buenos Aires, Argentina
ImClone Investigational Site
Caba, Argentina
ImClone Investigational Site
Rosario, Argentina
ImClone Investigational Site
Santa Fe, Argentina
ImClone Investigational Site
Bankstown, New South Wales, Australia
ImClone Investigational Site
Kogarah, New South Wales, Australia
ImClone Investigational Site
Liverpool, New South Wales, Australia
ImClone Investigational Site
Wollongong, New South Wales, Australia
ImClone Investigational Site
Southport, Queensland, Australia
ImClone Investigational Site
Kurralta Park, South Australia, Australia
ImClone Investigational Site
Coburg, Victoria, Australia
ImClone Investigational Site
Footscray, Victoria, Australia
ImClone Investigational Site
Frankston, Victoria, Australia
ImClone Investigational Site
Parkville, Victoria, Australia
ImClone Investigational Site
Graz, Austria
ImClone Investigational Site
Linz, Austria
ImClone Investigational Site
Steyr, Austria
ImClone Investigational Site
Vienna, Austria
ImClone Investigational Site
Bonheiden, Belgium
ImClone Investigational Site
Bruges, Belgium
ImClone Investigational Site
Brussels, Belgium
ImClone Investigational Site
Brussels, Belgium
ImClone Investigational Site
Edegem, Belgium
ImClone Investigational Site
Leuven, Belgium
ImClone Investigational Site
Belo Horizonte, Brazil
ImClone Investigational Site
Belo Horizonte, Brazil
ImClone Investigational Site
Caxias do Sul, Brazil
Showing 40 of 167 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.